Q1FY27 – Sakar Healthcare Records 38% YoY Revenue Growth PAT Rises 120%

Ahmedabad, 24th July 2026 : Sakar Healthcare Ltd |NSE: SAKAR, with a research-driven API-integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its unaudited financial results for the financial year ended 30th Jun 2026.

Q1FY27 Consolidated Financial Performance

Particulars (INR Lakhs)	Q1FY27	Q1FY26	Y-o-Y	FY26
Revenue from Operations	**7,297.25**	**5,273.62**	**38%**	**25,173.60**
Gross Profit	**3,839.03**	**2,378.38**	**61%**	**12,845.93**
Gross Profit Margin (%)	53%	45%		51%
EBITDA	**2,124.89**	**1,270.58**	**67%**	**6,888.82**
EBITDA Margin (%)	29%	24%		27%
Profit After Tax	**1,028.49**	**467.13**	**120%**	**3,048.46**
PAT Margin	14%	9%		12%

Business Highlights for Q1FY27

- Executed **more than 65 oncology product contracts**, with **over 50 commercial discussions** currently underway.
- Shared **261 dossiers globally**, of which **178 have been submitted** and **16 have received Marketing Authorisations**.
- Shared dossiers for **21 of the 32 developed oncology products**, securing **16 dossier approvals**.
- Completed **26 EU Marketing Authorisation filings**, including **15 owned filings**. Further **6 MAs** procured through partners in **Bulgaria and Bosnia**, rest has been filed that includes **Czech Republic, Croatia and Portugal**.
- **Sakar Healthcare** continues to strengthen its foundation for **long-term value creation**, backed by robust growth, **expanding oncology capabilities**, and a growing global footprint.
- Submitted **33 site variations covering 18 cytotoxic molecules** across the EU and the UK, of which **seven have been approved**.
- Developed **21 APIs in-house**, including, **16** APIs with Written Confirmation, **8** Commercialised products, **2** API's with CEP approval, **5** CEP applications currently in process.
- 33 Technology transfer projects for oncology products are underway with **Accord-Intas, Torrent in the UK and Germany, Emcure, Glenmark, and Zydus**. Of these projects, **7 have received site variation approvals—two in the UK and five in the EU**.

Financial Highlights for Q1 & FY27

- Revenue from operations for **Q1FY27** stood at **₹ 7,297 lakhs**, reflecting **38% YoY** growth. Performance was supported by new market authorizations with oncology products and strong demand across countries, alongside continued execution across key initiatives

- EBITDA increased to **₹ 2,125 lakhs**, up **67% YoY**; EBITDA margins stood at **29%**

- Company delivered a strong improvement in profitability, with PAT margin at **14%** expanding sharply YoY, reflecting operating leverage, improved efficiencies, and disciplined cost management

Commenting on the Results, Mr. Sanjay Shah, Managing Director *said,*
Q1FY27 marks another period of steady progress, supported by healthy year-on-year growth. The company remains on a strong growth trajectory in terms of both revenue and profitability, reinforcing the promising outlook for the business over the longer term. Our Oncology business remains a key pillar of our strategy. During the quarter, we expanded commercial engagements, strengthened export momentum, and advanced dossier submissions, Marketing Authorizations, site variation approvals, and technology transfer projects with leading global pharmaceutical partners. We also enhanced our integrated oncology platform by expanding our portfolio of in-house APIs supported by key regulatory certifications, reinforcing our capabilities and long-term competitive position.

Looking ahead, we remain confident that converting regulatory approvals into commercial launches and supplies, alongside growing export opportunities and the gradual ramp-up of oncology volumes, will improve capacity utilisation and operating leverage. Backed by a robust product pipeline, regulatory progress, and an expanding international presence, we are well positioned to deliver sustainable and profitable growth. Our long-term outlook remains promising, underpinned by the scalability of our oncology platform and the progressive commercialization of our product portfolio

About Sakar HealthCare Limited:

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. Sakar's oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles.

Contact Details

Sakar HealthCare Limited	Investor Relations: MUFG Intime India Private Limited
Sakar Healthcare Ltd.	MUFG
CIN - L24231GJ2004PLC043861	Mr. Nikunj Seth | Ms. Sejal Bhattar nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com
Mr. Dharmesh Thaker CFO info@sakarhealthcare.com	

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.